Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Impairment

v3.10.0.1
Impairment
12 Months Ended
Dec. 31, 2018
Asset Impairment Charges [Abstract]  
Impairment
Note Q – Impairment
The following table reconciles the asset impairment charges (in thousands), which are recognized in operating expenses in our consolidated statement of operations:
  For the Years Ended December 31,
  2018 2017 2016
Impairment of HDC Assets $ —  $ —  $ 1,902 
Impairment of Path Logic Assets —  —  1,562 
Total Impairment $ —  $ —  $ 3,464 

HDC Assets
This impairment charge is related to the Master License Agreement with Health Discovery Corporation.  This impairment charge writes off the HDC intangible assets associated with SVM, LDT, flow cytometry and cytogenetics technologies.  The impairment is primarily the result of the lack of revenues to date, and the disputed license termination notification received from HDC.  Based on this analysis, the Company determined that the assets were fully impaired, and an impairment loss was recorded for the unamortized balance of these assets.
Path Logic Assets
This impairment charge is associated with our Path Logic intangible assets, consisting of customer relationships.  Based on the analysis performed, this asset is fully impaired.